Navigation Links
According to a New Government Survey, 38 Percent of Adults and 12 Percent of Children Use Complementary and Alternative Medicine
Date:12/10/2008

ional Health Statistics Report by NCHS, are based on data from more than 23,300 interviews with American adults and more than 9,400 interviews with adults on behalf of a child in their household. The 2007 survey is the second conducted by NCCAM and NCHS --- the first was done as part of the 2002 NHIS (2).

CAM Use Among Adults

Comparison of the data from the 2002 and 2007 surveys suggests that overall use of CAM among adults has remained relatively steady --- 36 percent in 2002 and 38 percent in 2007. However, there has been substantial variation in the use of some specific CAM therapies, such asdeep breathing, meditation, massage therapy, and yoga, which all showed significant increases.

The most commonly used CAM therapies among U.S. adults were

  • Nonvitamin, nonmineral, natural products (17.7 percent)

Most common: fish oil/omega 3/DHA, glucosamine, echinacea, flaxseed oil or pills, and ginseng (3)

  • Deep breathing exercises (12.7 percent)
  • Meditation (9.4 percent)
  • Chiropractic or osteopathic manipulation (8.6 percent)
  • Massage (8.3 percent)
  • Yoga (6.1 percent).

Adults used CAM most often to treat pain including back pain or problems, neck pain or problems, joint pain or stiffness/other joint condition, arthritis, and other musculoskeletal conditions. Adult use of CAM therapies for head or chest colds showed a marked decrease from 2002 to 2007 (9.5 percent in 2002 to 2.0 percent in 2007).

Consistent with results from the 2002 data, in 2007 CAM use among adults was greater among:

  • Women (42.8 percent, compared to men 33.5 percent)
  • Those aged 30-69 (30-39 years: 39.6 percent, 40-49 years: 40.1 percent, 50-59 y
    '/>"/>

SOURCE National Institutes of Health; National Center for Complementary and Alternative Medicine
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine news :

1. Chicago Sit-In Highlights Laid-Off Workers, Employers Obligations, and WARN Act, According to Outten & Golden LLP
2. Exjade(R) Benefits Chronically Transfused Patients by Significantly Reducing Toxic Iron That Can Damage Key Organs, According to Landmark Trial
3. Major Retailers Experience 161% Increase in Attempted Hacker Attacks, According to SecureWorks
4. Economy Doesnt Dampen Colorados Giving Spirit According to Statewide Giving and Volunteering Study
5. Enrollment Growth in U.S. Nursing Colleges and Universities Hits an 8-Year Low According to New Data Released by AACN
6. Medtronic, Inc. and Medtronic Sofamor Danek, USA, Inc. Sued for Product Liability and Promoting the Off-Label Use of Infuse(R) Bone Graft Product, According to Page Perry, LLC
7. Cancer incidence and mortality drops among American men and women, according to annual report
8. Oregon, Washington State Doing the Most to Promote Roadway Safety, According to New Emergency Nurses Association National Scorecard
9. More Than Half of Consumers Going to Doctors Less Due to Rising Healthcare Costs, According to checkMD Survey : 38 Percent Lack Adequate Employer Healthcare Coverage
10. Pharmaceutical Industry Needs to Speed Up Transformation to Meet Changing Market Dynamics, According to Ernst & Young Report
11. Companies Pay a High Price for Employees With Crohns Disease and Ulcerative Colitis, According to Study From Thomson Reuters
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Medicine Technology:Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 2Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 3Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 4Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 5Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 6Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 7Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 8Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 9Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 10AdvanDx Receives FDA 510(k) Clearance for 90 Minutes PNA FISH(R) Protocol for Identifying Staphylococcal Bloodstream Pathogens 2AdvanDx Receives FDA 510(k) Clearance for 90 Minutes PNA FISH(R) Protocol for Identifying Staphylococcal Bloodstream Pathogens 3China-Biotics, Inc. to Hold 2009 Annual Meeting of Stockholders on March 5, 2010 2China-Biotics, Inc. to Hold 2009 Annual Meeting of Stockholders on March 5, 2010 3Trius Therapeutics Files Registration Statement for Proposed Initial Public Offering 6063 1Society of Interventional Radiology hosts oncology therapies Webinar offers resources 10650 1Society of Interventional Radiology hosts oncology therapies Webinar offers resources 10650 2Singing in Pregnancy May Be Harder Work 60872 1